The synthesis of retatrutide, a novel dual agonist targeting both GLP-1 website and GIP receptors, represents a complex several-stage synthetic process. Preliminary routes focused on protein portion coupling, utilizing solid-phase creation methodologies to build the long amino acid sequence. Subsequent study has explored alternative approaches, inc